Gemina Laboratories Stock Performance
| GLABF Stock | USD 0.57 0.02 3.64% |
Gemina Laboratories holds a performance score of 13 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 3.13, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Gemina Laboratories will likely underperform. Use Gemina Laboratories jensen alpha, maximum drawdown, semi variance, as well as the relationship between the sortino ratio and potential upside , to analyze future returns on Gemina Laboratories.
Risk-Adjusted Performance
13 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Gemina Laboratories are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite nearly unfluctuating fundamental drivers, Gemina Laboratories reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 881.9 K | |
| Total Cashflows From Investing Activities | 8197.00 |
Gemina |
Gemina Laboratories Relative Risk vs. Return Landscape
If you would invest 31.00 in Gemina Laboratories on September 4, 2024 and sell it today you would earn a total of 26.00 from holding Gemina Laboratories or generate 83.87% return on investment over 90 days. Gemina Laboratories is currently producing 1.1709% returns and takes up 7.0212% volatility of returns over 90 trading days. Put another way, 62% of traded otc stocks are less volatile than Gemina, and 77% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Gemina Laboratories Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Gemina Laboratories' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Gemina Laboratories, and traders can use it to determine the average amount a Gemina Laboratories' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1668
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | GLABF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.02 actual daily | 62 62% of assets are less volatile |
Expected Return
| 1.17 actual daily | 23 77% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average Gemina Laboratories is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Gemina Laboratories by adding it to a well-diversified portfolio.
Gemina Laboratories Fundamentals Growth
Gemina OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Gemina Laboratories, and Gemina Laboratories fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Gemina OTC Stock performance.
| Return On Equity | -3.47 | |||
| Return On Asset | -1.48 | |||
| Operating Margin | 979.18 % | |||
| Current Valuation | 17.22 M | |||
| Shares Outstanding | 64.1 M | |||
| Price To Book | 9.70 X | |||
| Price To Sales | 5,790 X | |||
| EBITDA | (4.69 M) | |||
| Cash And Equivalents | 2.95 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 12.47 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (3.87 M) | |||
| Earnings Per Share | (0.08) X | |||
| Total Asset | 1.42 M | |||
About Gemina Laboratories Performance
By analyzing Gemina Laboratories' fundamental ratios, stakeholders can gain valuable insights into Gemina Laboratories' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Gemina Laboratories has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Gemina Laboratories has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. It is developing POC Antigen COVID test, a point-of-care lateral flow assay test strip to test whether or not a person is currently infected with COVID-19. Gemina Laboratories operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5 people.Things to note about Gemina Laboratories performance evaluation
Checking the ongoing alerts about Gemina Laboratories for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Gemina Laboratories help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Gemina Laboratories is way too risky over 90 days horizon | |
| Gemina Laboratories has some characteristics of a very speculative penny stock | |
| Gemina Laboratories appears to be risky and price may revert if volatility continues | |
| Gemina Laboratories has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (4.73 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Gemina Laboratories has accumulated about 2.95 M in cash with (3.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05. | |
| Roughly 56.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Why Is Purple Biotech Stock Trading Higher On Monday |
- Analyzing Gemina Laboratories' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Gemina Laboratories' stock is overvalued or undervalued compared to its peers.
- Examining Gemina Laboratories' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Gemina Laboratories' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Gemina Laboratories' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Gemina Laboratories' otc stock. These opinions can provide insight into Gemina Laboratories' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Gemina OTC Stock analysis
When running Gemina Laboratories' price analysis, check to measure Gemina Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gemina Laboratories is operating at the current time. Most of Gemina Laboratories' value examination focuses on studying past and present price action to predict the probability of Gemina Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gemina Laboratories' price. Additionally, you may evaluate how the addition of Gemina Laboratories to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| CEOs Directory Screen CEOs from public companies around the world |